Which has preferable valuation & earnings, WGS or FLGT?

GeneDx has higher revenue and earnings than Fulgent Genetics. GeneDx is trading at a lower price-to-earnings ratio than Fulgent Genetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GeneDx $427.54M 4.03 -$21.02M -$2.68 N/A Fulgent Genetics $322.67M 1.60 -$60.51M -$2.39 N/A

Is WGS or FLGT more profitable?

GeneDx has a net margin of -17.58% compared to Fulgent Genetics' net margin of -23.04%. GeneDx's return on equity of 9.15% beat Fulgent Genetics' return on equity. Company Net Margins Return on Equity Return on Assets GeneDx -17.58% 9.15% 5.21% Fulgent Genetics -23.04% -3.24% -2.97%

Fulgent Genetics (FLGT) Competitors

$18.18 +0.34 (+1.91%)

Closing price 06/23/2026 04:00 PM Eastern

Extended Trading

$17.85 -0.33 (-1.81%)

As of 04:40 AM Eastern

Compare

FLGT vs. SGRY, AGL, WGS, ADUS, and SNDA

Should you buy Fulgent Genetics stock or one of its competitors? MarketBeat compares Fulgent Genetics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Fulgent Genetics include Surgery Partners (SGRY), Agilon Health (AGL), GeneDx (WGS), Addus HomeCare (ADUS), and Sonida Senior Living (SNDA). These companies are all part of the "healthcare" industry.

How does Fulgent Genetics compare to Surgery Partners?

Fulgent Genetics (NASDAQ:FLGT) and Surgery Partners (NASDAQ:SGRY) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.

Fulgent Genetics has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market. Comparatively, Surgery Partners has a beta of 1.96, indicating that its share price is 96% more volatile than the broader market.

48.1% of Fulgent Genetics shares are owned by institutional investors. 36.2% of Fulgent Genetics shares are owned by company insiders. Comparatively, 2.0% of Surgery Partners shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Surgery Partners has a net margin of -2.28% compared to Fulgent Genetics' net margin of -23.04%. Surgery Partners' return on equity of 1.04% beat Fulgent Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulgent Genetics	-23.04%	-3.24%	-2.97%
Surgery Partners	-2.28%	1.04%	0.41%

Fulgent Genetics currently has a consensus target price of $27.00, suggesting a potential upside of 48.51%. Surgery Partners has a consensus target price of $22.18, suggesting a potential upside of 52.66%. Given Surgery Partners' stronger consensus rating and higher possible upside, analysts clearly believe Surgery Partners is more favorable than Fulgent Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Surgery Partners	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Surgery Partners had 2 more articles in the media than Fulgent Genetics. MarketBeat recorded 2 mentions for Surgery Partners and 0 mentions for Fulgent Genetics. Surgery Partners' average media sentiment score of 0.95 beat Fulgent Genetics' score of 0.00 indicating that Surgery Partners is being referred to more favorably in the news media.

Company	Overall Sentiment
Fulgent Genetics	Neutral
Surgery Partners	Positive

Fulgent Genetics has higher earnings, but lower revenue than Surgery Partners. Surgery Partners is trading at a lower price-to-earnings ratio than Fulgent Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulgent Genetics	$322.67M	1.60	-$60.51M	-$2.39	N/A
Surgery Partners	$3.31B	0.57	-$77.90M	-$0.60	N/A

Summary

Surgery Partners beats Fulgent Genetics on 12 of the 17 factors compared between the two stocks.

How does Fulgent Genetics compare to Agilon Health?

Agilon Health (NYSE:AGL) and Fulgent Genetics (NASDAQ:FLGT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

Agilon Health has a net margin of -6.09% compared to Fulgent Genetics' net margin of -23.04%. Fulgent Genetics' return on equity of -3.24% beat Agilon Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agilon Health	-6.09%	-146.03%	-24.55%
Fulgent Genetics	-23.04%	-3.24%	-2.97%

48.1% of Fulgent Genetics shares are owned by institutional investors. 2.3% of Agilon Health shares are owned by insiders. Comparatively, 36.2% of Fulgent Genetics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Agilon Health had 1 more articles in the media than Fulgent Genetics. MarketBeat recorded 1 mentions for Agilon Health and 0 mentions for Fulgent Genetics. Agilon Health's average media sentiment score of 0.60 beat Fulgent Genetics' score of 0.00 indicating that Agilon Health is being referred to more favorably in the media.

Company	Overall Sentiment
Agilon Health	Positive
Fulgent Genetics	Neutral

Fulgent Genetics has lower revenue, but higher earnings than Agilon Health. Fulgent Genetics is trading at a lower price-to-earnings ratio than Agilon Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agilon Health	$5.82B	0.32	-$391.35M	-$21.56	N/A
Fulgent Genetics	$322.67M	1.60	-$60.51M	-$2.39	N/A

Agilon Health presently has a consensus target price of $58.73, indicating a potential downside of 47.16%. Fulgent Genetics has a consensus target price of $27.00, indicating a potential upside of 48.51%. Given Fulgent Genetics' higher possible upside, analysts plainly believe Fulgent Genetics is more favorable than Agilon Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agilon Health	2 Sell rating(s)	8 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.20
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Agilon Health has a beta of 3, meaning that its share price is 200% more volatile than the broader market. Comparatively, Fulgent Genetics has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market.

Summary

Fulgent Genetics beats Agilon Health on 8 of the 15 factors compared between the two stocks.

How does Fulgent Genetics compare to GeneDx?

GeneDx (NASDAQ:WGS) and Fulgent Genetics (NASDAQ:FLGT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

GeneDx has higher revenue and earnings than Fulgent Genetics. GeneDx is trading at a lower price-to-earnings ratio than Fulgent Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeneDx	$427.54M	4.03	-$21.02M	-$2.68	N/A
Fulgent Genetics	$322.67M	1.60	-$60.51M	-$2.39	N/A

GeneDx has a beta of 1.96, meaning that its stock price is 96% more volatile than the broader market. Comparatively, Fulgent Genetics has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market.

GeneDx currently has a consensus price target of $86.86, indicating a potential upside of 49.55%. Fulgent Genetics has a consensus price target of $27.00, indicating a potential upside of 48.51%. Given GeneDx's stronger consensus rating and higher possible upside, equities research analysts plainly believe GeneDx is more favorable than Fulgent Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeneDx	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

61.7% of GeneDx shares are held by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are held by institutional investors. 25.2% of GeneDx shares are held by insiders. Comparatively, 36.2% of Fulgent Genetics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

GeneDx has a net margin of -17.58% compared to Fulgent Genetics' net margin of -23.04%. GeneDx's return on equity of 9.15% beat Fulgent Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeneDx	-17.58%	9.15%	5.21%
Fulgent Genetics	-23.04%	-3.24%	-2.97%

In the previous week, GeneDx had 36 more articles in the media than Fulgent Genetics. MarketBeat recorded 36 mentions for GeneDx and 0 mentions for Fulgent Genetics. GeneDx's average media sentiment score of 0.17 beat Fulgent Genetics' score of 0.00 indicating that GeneDx is being referred to more favorably in the media.

Company	Overall Sentiment
GeneDx	Neutral
Fulgent Genetics	Neutral

Summary

GeneDx beats Fulgent Genetics on 13 of the 16 factors compared between the two stocks.

How does Fulgent Genetics compare to Addus HomeCare?

Addus HomeCare (NASDAQ:ADUS) and Fulgent Genetics (NASDAQ:FLGT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment.

Addus HomeCare has a net margin of 6.89% compared to Fulgent Genetics' net margin of -23.04%. Addus HomeCare's return on equity of 9.80% beat Fulgent Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Addus HomeCare	6.89%	9.80%	7.34%
Fulgent Genetics	-23.04%	-3.24%	-2.97%

In the previous week, Addus HomeCare had 4 more articles in the media than Fulgent Genetics. MarketBeat recorded 4 mentions for Addus HomeCare and 0 mentions for Fulgent Genetics. Fulgent Genetics' average media sentiment score of 0.00 beat Addus HomeCare's score of -0.50 indicating that Fulgent Genetics is being referred to more favorably in the news media.

Company	Overall Sentiment
Addus HomeCare	Negative
Fulgent Genetics	Neutral

Addus HomeCare has higher revenue and earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Addus HomeCare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Addus HomeCare	$1.42B	1.26	$95.91M	$5.41	17.76
Fulgent Genetics	$322.67M	1.60	-$60.51M	-$2.39	N/A

95.4% of Addus HomeCare shares are held by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are held by institutional investors. 4.1% of Addus HomeCare shares are held by company insiders. Comparatively, 36.2% of Fulgent Genetics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Addus HomeCare presently has a consensus target price of $131.00, indicating a potential upside of 36.33%. Fulgent Genetics has a consensus target price of $27.00, indicating a potential upside of 48.51%. Given Fulgent Genetics' higher possible upside, analysts clearly believe Fulgent Genetics is more favorable than Addus HomeCare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Addus HomeCare	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.70
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Addus HomeCare has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market. Comparatively, Fulgent Genetics has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market.

Summary

Addus HomeCare beats Fulgent Genetics on 12 of the 17 factors compared between the two stocks.

How does Fulgent Genetics compare to Sonida Senior Living?

Sonida Senior Living (NYSE:SNDA) and Fulgent Genetics (NASDAQ:FLGT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, risk, analyst recommendations, earnings and institutional ownership.

Fulgent Genetics has lower revenue, but higher earnings than Sonida Senior Living. Fulgent Genetics is trading at a lower price-to-earnings ratio than Sonida Senior Living, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sonida Senior Living	$411.85M	4.21	-$70.78M	-$5.83	N/A
Fulgent Genetics	$322.67M	1.60	-$60.51M	-$2.39	N/A

Sonida Senior Living presently has a consensus price target of $40.50, suggesting a potential upside of 10.72%. Fulgent Genetics has a consensus price target of $27.00, suggesting a potential upside of 48.51%. Given Fulgent Genetics' higher probable upside, analysts plainly believe Fulgent Genetics is more favorable than Sonida Senior Living.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sonida Senior Living	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Sonida Senior Living has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market. Comparatively, Fulgent Genetics has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market.

In the previous week, Sonida Senior Living's average media sentiment score of 1.81 beat Fulgent Genetics' score of 0.00 indicating that Sonida Senior Living is being referred to more favorably in the media.

Company	Overall Sentiment
Sonida Senior Living	Very Positive
Fulgent Genetics	Neutral

Fulgent Genetics has a net margin of -23.04% compared to Sonida Senior Living's net margin of -24.15%. Fulgent Genetics' return on equity of -3.24% beat Sonida Senior Living's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sonida Senior Living	-24.15%	-36.98%	-7.08%
Fulgent Genetics	-23.04%	-3.24%	-2.97%

87.6% of Sonida Senior Living shares are held by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are held by institutional investors. 39.3% of Sonida Senior Living shares are held by insiders. Comparatively, 36.2% of Fulgent Genetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Fulgent Genetics beats Sonida Senior Living on 7 of the 13 factors compared between the two stocks.

Get Fulgent Genetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FLGT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FLGT vs. The Competition

Export

Metric	Fulgent Genetics	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$506.67M	$1.54B	$6.45B	$12.38B
Dividend Yield	N/A	N/A	2.69%	5.83%
P/E Ratio	-7.61	77.66	24.66	23.99
Price / Sales	1.60	7.31	526.33	107.23
Price / Cash	N/A	23.50	44.82	54.51
Price / Book	0.51	5.16	10.72	6.50
Net Income	-$60.51M	-$54.76M	$3.56B	$336.88M
7 Day Performance	2.71%	-0.61%	0.94%	-0.16%
1 Month Performance	6.25%	-3.64%	0.36%	0.76%
1 Year Performance	-6.86%	-4.16%	29.67%	28.49%

Fulgent Genetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FLGT Fulgent Genetics	2.1458 of 5 stars	$18.18 +1.9%	$27.00 +48.5%	-5.9%	$506.67M	$322.67M	N/A	1,315
SGRY Surgery Partners	3.7638 of 5 stars	$15.14 +0.1%	$22.18 +46.5%	-28.1%	$1.98B	$3.31B	N/A	16,000
AGL Agilon Health	1.61 of 5 stars	$113.19 -1.0%	$58.73 -48.1%	+106.3%	$1.89B	$5.93B	N/A	1,076	News Coverage Gap Down
WGS GeneDx	4.6152 of 5 stars	$60.60 -1.2%	$96.43 +59.1%	-27.1%	$1.80B	$427.54M	N/A	1,300	Trending News Analyst Forecast
ADUS Addus HomeCare	3.6459 of 5 stars	$94.71 -0.1%	$131.00 +38.3%	-15.0%	$1.77B	$1.42B	17.51	50,659	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FLGT) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fulgent Genetics (FLGT) Competitors

FLGT vs. SGRY, AGL, WGS, ADUS, and SNDA

How does Fulgent Genetics compare to Surgery Partners?

Summary

How does Fulgent Genetics compare to Agilon Health?

Summary

How does Fulgent Genetics compare to GeneDx?

Summary

How does Fulgent Genetics compare to Addus HomeCare?

Summary

How does Fulgent Genetics compare to Sonida Senior Living?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLGT vs. The Competition

Fulgent Genetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fulgent Genetics (FLGT) Competitors

FLGT vs. SGRY, AGL, WGS, ADUS, and SNDA

How does Fulgent Genetics compare to Surgery Partners?

Which has more volatility & risk, FLGT or SGRY?

Do insiders & institutionals have more ownership in FLGT or SGRY?

Is FLGT or SGRY more profitable?

Do analysts rate FLGT or SGRY?

Does the media prefer FLGT or SGRY?

Which has better earnings and valuation, FLGT or SGRY?

Summary

How does Fulgent Genetics compare to Agilon Health?

Is AGL or FLGT more profitable?

Do insiders & institutionals have more ownership in AGL or FLGT?

Does the media prefer AGL or FLGT?

Which has higher earnings and valuation, AGL or FLGT?

Do analysts prefer AGL or FLGT?

Which has more volatility and risk, AGL or FLGT?

Summary

How does Fulgent Genetics compare to GeneDx?

Which has preferable valuation & earnings, WGS or FLGT?

Which has more volatility & risk, WGS or FLGT?

Do analysts prefer WGS or FLGT?

Do insiders and institutionals hold more shares of WGS or FLGT?

Is WGS or FLGT more profitable?

Does the media favor WGS or FLGT?

Summary

How does Fulgent Genetics compare to Addus HomeCare?

Is ADUS or FLGT more profitable?

Does the media favor ADUS or FLGT?

Which has stronger valuation and earnings, ADUS or FLGT?

Do insiders & institutionals hold more shares of ADUS or FLGT?

Do analysts prefer ADUS or FLGT?

Which has more risk and volatility, ADUS or FLGT?

Summary

How does Fulgent Genetics compare to Sonida Senior Living?

Which has higher valuation and earnings, SNDA or FLGT?

Do analysts recommend SNDA or FLGT?

Which has more volatility and risk, SNDA or FLGT?

Does the media prefer SNDA or FLGT?

Is SNDA or FLGT more profitable?

Do institutionals & insiders hold more shares of SNDA or FLGT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLGT vs. The Competition

Fulgent Genetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools